Edition:
United States

Novo Nordisk Settles U.S. Patent Litigation Case On Victoza With Teva


Monday, 18 Mar 2019 07:02am EDT 

March 18 (Reuters) - Novo Nordisk A/S ::REG-NOVO NORDISK SETTLES U.S. PATENT LITIGATION CASE ON VICTOZA® (LIRAGLUTIDE) WITH TEVA.SAYS TEVA IS LICENSED TO LAUNCH A GENERIC VERSION OF VICTOZAAS OF 22 DECEMBER 2023.UNDER CERTAIN CIRCUMSTANCES TEVA COULD LAUNCH A GENERIC VERSION OF VICTOZA(®) EARLIER, BUT NOT BEFORE 22 MARCH 2023, UNLESS VICTOZA(®) PATENTS ARE NO LONGER IN FORCE OR THERE IS ANOTHER GENERIC VERSION OF VICTOZA(®) ON MARKET.SAYS IF NOVO NORDISK IS GRANTED SIX MONTHS PAEDIATRIC EXTENSION FOR VICTOZA(®), ALL ABOVE-MENTIONED TIMELINES WILL BE EXTENDED BY SIX MONTHS.SAYS - AGREEMENT IS SUBJECT TO REVIEW BY US FEDERAL TRADE COMMISSION AND US DEPARTMENT OF JUSTICE.